Adjuvant vinorelbine plus cisplatin versus observation in patients with completely resected stage IB–IIIA non-small-cell lung cancer (Adjuvant Navelbine International Trialist Association [ANITA]): a randomised controlled trial
The Lancet OncologyPublished 18 August 2006
Jean‐Yves Douillard, Rafael Rosell, Mario De Lena, Francesco Carpagnano, Rodryg Ramlau, J.L. González-Larriba
Citations1,565
SJR quartileQ1
SJR score11.32
SNIP10.23
Generate an AI Snapshot to get a quick, structured summary of this paper.
Study Snapshot
ObjectiveStudy objective
MethodsResearch methodology
PopulationPopulation studied
Sample sizeSample sizes
OutcomesStudy outcomes here
ResultsStudy results comes here
LimitationsResearch study limitations comes here
A concise AI-generated summary of the paper will appear here once you click Generate AI Snapshot.
TL;DR
Adjuvant vinorelbine plus cisplatin extends survival in patients with completely resected NSCLC, better defining indication of adjuvant chemotherapy.
Abstract
Adjuvant vinorelbine plus cisplatin extends survival in patients with completely resected NSCLC, better defining indication of adjuvant chemotherapy.
Keywords
Medicine
International Journal of CancerEstimating the world cancer burden: Globocan 2000
3,744 Citations2001D. Maxwell Parkin, Freddie Bray +2 more
GLOBOCAN 2000 updates the previous data-based global estimates of incidence, mortality and prevalence to the year 2000 and uses a “databased” approach, rather different from themodeling method used in other estimates.
BMJChemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials
2,850 Citations1995Non-small Cell Lung Cancer Collaborative Group
The results of this meta-analysis suggest that chemotherapy may have a role in treating non-small cell lung cancer, and reached conventional levels of significance when used with radical radiotherapy and with supportive care.
New England Journal of MedicineCisplatin-Based Adjuvant Chemotherapy in Patients with Completely Resected Non–Small-Cell Lung Cancer
2,336 Citations2004R. Arriagada
Cisplatin-based adjuvant chemotherapy improves survival among patients with completely resected non-small-cell lung cancer and had a significantly higher survival rate than those assigned to observation.
New England Journal of MedicineVinorelbine plus Cisplatin vs. Observation in Resected Non–Small-Cell Lung Cancer
1,815 Citations2005Timothy Winton, Robert B. Livingston +19 more
Adjuvant vinorelbine plus cisplatin has an acceptable level of toxicity and prolongs disease-free and overall survival among patients with completely resected early-stage non-small-cell lung cancer.
New England Journal of MedicineA Randomized Trial of Adjuvant Chemotherapy with Uracil–Tegafur for Adenocarcinoma of the Lung
839 Citations2004Harubumi Kato, Yukito Ichinose +9 more
Adjuvant chemotherapy with uracil-tegafur improves survival among patients with completely resected pathological stage I adenocarcinoma of the lung.
JNCI Journal of the National Cancer InstituteRandomized Study of Adjuvant Chemotherapy for Completely Resected Stage I, II, or IIIA Non-Small-Cell Lung Cancer
599 Citations2003Giorgio V. Scagliotti
This randomized trial failed to prospectively confirm a statistically significant role for adjuvant chemotherapy in completely resected NSCLC and given the poor compliance with the MVP regimen used in this study, future studies should explore more effective treatments.
New England Journal of MedicineA Randomized Trial of Postoperative Adjuvant Therapy in Patients with Completely Resected Stage II or IIIa Non–Small-Cell Lung Cancer
450 Citations2000Steven M. Keller, Sudeshna Adak +7 more
As compared with radiotherapy alone, adjuvant radiotherapy and chemotherapy with cisplatin and etoposide does not decrease the risk of intrathoracic recurrence or prolong survival in patients with completely resected stage II or IIIa non-small-cell lung cancer.
European Journal of Cardio-Thoracic SurgeryChemotherapy for patients with non-small cell lung cancer: the surgical setting of the Big Lung Trial1
389 Citations2004David Waller, Michael Peake +7 more
This trial has failed to observe a survival benefit with adjuvant chemotherapy following complete resection of stage I-III NSCLC, but the hazard ratio and 95% confidence intervals are consistent with the previously reported meta-analysis and two large recently reported trials, which suggest a small survival Benefit with cisplatin-based chemotherapy.
CancerTen-year survey of lung cancer treatment and survival in hospitals in the United States
263 Citations1999Willard A. Fry, Jerri Linn Phillips +1 more
This review focuses on primary lung cancer, which accounts for approximately 14% of all new cancers and 28% of cancer deaths in the U.S.
Journal of Clinical OncologyRole of Adjuvant Chemotherapy in Patients With Resected Non–Small-Cell Lung Cancer: Reappraisal With a Meta-Analysis of Randomized Controlled Trials
198 Citations2004Katsuyuki Hotta, Keitaro Matsuo +4 more
Journal of Clinical OncologyAdjuvant chemotherapy in stage IB non-small cell lung cancer (NSCLC): Update of Cancer and Leukemia Group B (CALGB) protocol 9633
178 Citations2006Gary M. Strauss, James E. Herndon +8 more
This updated but "preliminary" analysis no longer shows a significant OS advantage for adjuvant chemotherapy in stage IB NSCLC, however, the re-designed study does not have adequate power to detect small differences in OS that may be clinically significant.
Journal of Clinical OncologyLung Adjuvant Cisplatin Evaluation (LACE): A pooled analysis of five randomized clinical trials including 4,584 patients
157 Citations2006Jean‐Pierre Pignon, Hélène Tribodet +5 more
It is suggested that platinum-based adjuvant chemotherapy may not benefit stage I-A patients, and adjuvant cisplatin-based chemotherapy improves survival in patients with NSCLC.
CHEST JournalValue of the New TNM Staging System for Lung Cancer
76 Citations1989Clifton F. Mountain
The new staging system is of value for classifying patients according to clinical criteria into 5 specific disease extent groups that have a definite relationship to prognosis and the structure of treatment regimens that can be based on realistic expectations for improvement in survival.
Hematology/Oncology Clinics of North AmericaAdjuvant Chemotherapy of Lung Cancer: Methodologic Issues and Therapeutic Advances
46 Citations2005Gary M. Strauss
This article discusses methodologic issues relevant to the interpretation of recent studies focusing on adjuvant chemotherapy of lung cancer and attempts to conclude where the field is currently stand.
Clinical Cancer ResearchPatient Subsets Benefiting from Adjuvant Therapy Following Surgical Resection of Non–Small Cell Lung Cancer
17 Citations2005Bruce E. Johnson, Michael S. Rabin
Information available at the current time supports the administration of chemotherapy for patients with stages IB and II NSCLC, and further research will be needed to define the role of adjuvant chemotherapy and its use in conjunction with chest radiotherapy for the treatment of patients with resected stages IA and IIIANSCLC.